$ICU
If CEO, @SchlorffEric, and CFO David Green are publicly criticizing the marketcap of @SeaStarMedical for being undervalued at ~$15m (now under $14m)...
Should these execs be buying shares with their generous (Schlorff, 2023, $420k) annual salary?
Most tax loss related selling should be over in biotech companies.
Often money is made in companies where stock prices are down huge for quite some time despite positive news, earnings and fundamentals.
Traders usually exit on few ticks down because they often focus on charts
@dallascowboys y’all need to fuckin bench #CooperRush
He is bad. Like really bad. Unless you want a better draft pick, then leave him in.
But his trash play is killing the team demeanor.
Look at Ceedee and Micah’s expressions…
Everyone is sick of the mediocrity.
Do better.
@dallascowboys Let’s be honest.
Cooper Rush is just a loser and Mike McCarthy’s play calling is lacking.
Look at the drives where CeeDee has 2/3+ catches, and see how many of those end in TD’s.
Throw to Ceedee.
Opens up the run for Dowdle.
Opens up other receivers.
Fucking embarrassing.
$SLS will fail because it's a therapeutic cancer vaccine for AML with a bull case that revolves around pooled survival increases and no adequately controlled monotherapy data for a drug that's been in the clinic for about 15 years.
RCT's that I expect to fail in the next couple of months:
$ANAB (both readouts)
$BMEA T2D
$CRDF CRC
$CADL Prostate cancer
$CRVO LBD
$GALT NASH
$NMRA MDD
SAVA Alz
$SLS AML
$SYRS MDS
Happy to swap notes and/or thoughts on structure. Some of these are more of a pain than others.
@plainyogurt21@Biotenic I'm just a mere studier of fundamental and technical analysis. Chart has been clear as day if you've looked long enough.
Unfortunately, I'm not a keyboard doctor. Seems to me that different trial could mean different outcome. $21m enough for IA? Yes.
I'll take my chances.
BOL.
@plainyogurt21@Biotenic Well thought out thesis and diligence?
"Simple trial design and they have almost no money"
"Therapeutic cancer vaccines haven't worked"
"I see parallels to GLYC in the setup, data, types of people"
"A WT1 has already failed"
Still waiting for the thought out thesis/diligence
@A_May_MD@Biotenic Pretty clear to see that market makers and HFs disagree with his analysis.
But i’ll wait for him to share some of those hallowed notes on why he believes that.
Him posting a list like that is no more valuable than a “permabull” posting.